The purpose of HTA is to provide high-quality information to decision makers about the clinical effectiveness, cost-effectiveness, and broader impact of drugs, medical technologies, and health systems.
Biological medicines are far more complex and usually much bigger than chemical medicines, which
There is no common European consensus on how to reward healthcare innovation.
Manufacturing biological medicines is generally more complex than the production of traditional (
The biotech industry proposes the development of shared European standards for HTAs to ensure the
Innovative medicines generally benefit from a certain period of intellectual property protection